Vaxcyte (PCVX) Stock Statistics & Valuation Metrics

Vaxcyte has a market cap or net worth of $8.89B. The enterprise value is $8.95B.

Vaxcyte has 143,920,360 shares outstanding. The number of shares has decreased by -2.65% in one year.

Vaxcyte’s return on equity (ROE) is -0.29 and return on invested capital (ROIC) is -32.45%.

The current PE Ratio of Vaxcyte is ―. Vaxcyte’s PEG ratio is -0.17.

In the last 12 months, Vaxcyte had revenue of 0.00 and earned -766.63M in profits. Earnings per share was -5.63.

In the last 12 months, operating cash flow was -655.58M and capital expenditures -13.71M, giving a free cash flow of -669.29M billion.

Vaxcyte pays an annual dividend of ―, resulting in a dividend yield of ―

Vaxcyte upcoming earnings date is May 11, 2026, After Close (Confirmed).

Vaxcyte as a current ratio of 7.91, with Debt / Equity ratio of 8.52%

In the past 12 months, Vaxcyte has paid 0.00 in taxes.

Vaxcyte EV to EBITDA ratio is -8.54, with an EV/FCF ratio of -9.46.

Vaxcyte has $1.56B in cash and marketable securities with $228.84M in debt, giving a net cash position of $1.33B billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Vaxcyte is $105.14, which is 11.43% higher than the current price. The consensus rating is Strong Buy